Mesoblast (MESO) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Taysha Gene Therapies (TSHA) has outperformed Mesoblast (MESO) over the past year, losing 6.1% versus a loss of 22.9%. Over five years, MESO leads with a +22.7% price change compared with -75.2% for TSHA. Mesoblast is the larger company by market cap ($1.76 billion vs $1.44 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MESO | TSHA |
|---|---|---|
| Share price | $13.52 | $4.41 |
| Market cap | $1.76B | $1.44B |
| 1-day change | -3.01% | -0.56% |
| YTD return | -22.73% | -19.45% |
| 1-year return | -22.94% | -6.14% |
| 5-year return | +22.71% | -75.22% |
| Forward P/E | 29.71 | — |
| EPS (TTM) | $-0.44 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.50 | $7.30 |
| 52-week low | $13.05 | $3.69 |
| Distance from 52-week high | -37.12% | -39.66% |
| Analyst consensus | buy | none |
| Avg. price target upside | +173.67% | +195.12% |
| Average volume | 232.53K | 3.26M |
| Shares outstanding | 129.85M | 325.83M |
| Employees | 108 | 99 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TSHA has outperformed MESO by 16.8 percentage points over the past year.
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 99 employees
MESO vs TSHA FAQ
Which is bigger, Mesoblast or Taysha Gene Therapies?
Mesoblast (MESO) is larger, with a market capitalization of $1.76B compared with $1.44B for Taysha Gene Therapies (TSHA).
Which stock has performed better over the past year, MESO or TSHA?
TSHA returned -6.14% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Mesoblast and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.